Table 2.

Meta-analysis results for the prevalence of MIH globally in 5-year intervals. The number of studies used to calculate each estimate is indicated in brackets

Global MIH prevalence according to	2000–2005	2006–2010	2011–2015	2016–2020	p-value
\Year of publication (N = 92)	15.1% (8.8–21.3) N = 6	15.3% (11.9–18.7) N = 17	14.7% (12.9–16.5) N = 31	13.7% (11.6–15.7) N = 38	0.809
Reported year of examination (N = 65)	19.2% (10.6–27.9) N = 6	16.6% (12.6–20.5) N = 17	14.1% (12.1–16.2) N = 16	17.8% (14.3–21.2) N = 26	0.221
Estimated year of examination (N = 127)	15.7% (10.0–21.5) N = 9	15.3% (12.6–18.1) N = 26	13.6% (11.7–15.4) N = 41	16.1% (14.3–17.8) N = 51	0.284

MIH prevalence was not calculated for studies before 2000 due to the low number of studies and inconsistent diagnosis criteria. Similarly, calculations were not performed for studies after 2020 because many clinical trials were cancelled or postponed in 20212023 due to the COVID-19 pandemic. Additionally, this interval did not meet the required 5-year observation period making it incomparable to earlier intervals